Extended Data Fig. 2: Consolidated Standards of Reporting Trials (CONSORT) flow diagram. | Nature Medicine

Extended Data Fig. 2: Consolidated Standards of Reporting Trials (CONSORT) flow diagram.

From: Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Extended Data Fig. 2

Flow diagram depicts the disposition of patients throughout the phases of the study, including screening, randomization to neoadjuvant treatment and surgery. Reasons for screen failures, no completion of planned neoadjuvant therapy and surgery not performed, or surgery performed off trial are shown. SAE, serious adverse event, TRAE, treatment-related adverse event; PD, progressive disease; PS, performance status.

Back to article page